Marinus Pharmaceuticals Wraps Phase 3 Trial Enrollment for Tuberous Sclerosis Complex Treatment, Targets New Drug Application in 2025 Following Phase 3 Seizure Treatment Trial
Portfolio Pulse from Benzinga Newsdesk
Marinus Pharmaceuticals (NASDAQ:MRNS) has completed enrollment for its Phase 3 TrustTSC trial evaluating ganaxolone for treating seizures in tuberous sclerosis complex (TSC) patients. Topline data is expected in Q4 2024, with a New Drug Application targeted for April 2025. A new method of use patent for ganaxolone in TSC has also been granted, expiring in 2040.
May 17, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Marinus Pharmaceuticals has completed enrollment for its Phase 3 trial for ganaxolone in TSC treatment, with topline data expected in Q4 2024 and a New Drug Application targeted for April 2025. A new patent has also been granted, expiring in 2040.
The completion of Phase 3 trial enrollment and the anticipation of topline data in Q4 2024 are significant milestones. The targeted NDA submission in April 2025 and the new patent grant further strengthen Marinus' position, likely leading to positive short-term stock price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100